Key facts
- Alleviate’s last known valuation is $10.5M (Feb 2023).
- It has raised $4.7M across 4 recorded rounds; the latest was Seed Round ($275K) in Apr 2025.
- Notable investors include Kenston Capital Partners, Oregon Sports Angels, TCA Venture Group.
- Alleviate has filed 4 Form Ds with the SEC since 2022, most recently Apr 2025 ($275K sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Alleviate
Funding rounds
4 roundsAbout Alleviate
Developer of musculoskeletal pain relief devices designed for chronic pathologies. The company offers fully integrated solutions with products to treat, protect, and guide the recovery process for patients, as well as tracks pain and function progress with patient-reported outcomes data collection, enabling patients to relieve foot pain, repair scar tissue, and rebuild the arch in the long term.
- Sector
- Healthcare
- HQ
- Brighton, MA, United States
- Founded
- 2020
- Employees
- 9
- Website
- alleviatetherapy.com/
- Ownership
- Privately Held (backing)
Alleviate doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alleviate shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alleviate in its N-PORT filings yet. We sweep new filings monthly.